


ASN Kidney Week 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success

ASN Kidney Week 2026 Preview – Table of Contents

• <u>New Trends in Nephrology Treatment Strategy At ASN '26</u>	<u>3-5</u>
• <u>Key Sessions To Watch</u>	<u>6-7</u>
• <u>Industry-sponsored Sessions & Focus Areas At ASN 2026</u>	<u>8-18</u>
• <u>Competitive Landscape At a Glance at ASN 2026</u>	<u>9-10</u>
• <u>Key Industry-sponsored Sessions At ASN 2026</u>	<u>11-18</u>
• <u>New Entrants</u>	<u>19</u>
• <u>AI/ML Trends & Strategic Watchpoints At ASN 2026</u>	<u>20-22</u>
• <u>AI / Digital Health Angle At ASN 2026</u>	<u>21-22</u>
• <u>What We're Watching For Post-congress</u>	<u>23</u>
• <u>Get In Touch With LucidQuest</u>	<u>24</u>



ASN Kidney Week'26– New Trends in Nephrology Treatment Strategy (1/3)



• **IgAN will become a multi-mechanism treatment sequencing challenge**

- ASN Kidney Week 2026 will bring together data for povetacicept, atacicept, sibeprenlimab, zigakibart, iptacopan, sparsentan, sefaxersen and other targeted IgAN approaches. The key question will be how nephrologists will differentiate and sequence APRIL/BAFF inhibition, complement blockade, endothelin targeting and other mechanisms as differences in proteinuria, eGFR, durability, safety and treatment burden become increasingly important



• **Complement inhibition will broaden beyond individual kidney diseases**

- Presentations involving iptacopan, pegcetacoplan, ravulizumab, crovalimab and other complement-directed approaches will span IgAN, C3 glomerulopathy, IC-MPGN, aHUS and other complement-mediated kidney diseases. The strategic question will be whether targeting different points in the complement cascade will create distinct treatment positions based on disease biology, efficacy, safety and administration





• **Immune-mediated kidney disease will test how deep immune depletion should go**

- ASN will feature approaches ranging from conventional B-cell depletion to obinutuzumab, budoprutug, anti-CD38 strategies and FT819 anti-CD19 CAR-T across lupus nephritis, membranous nephropathy and other immune-mediated kidney diseases. The key tension will be whether deeper targeting of B cells, plasmablasts or plasma cells will produce sufficiently durable renal responses to justify greater treatment complexity and immunologic risk



• **APOL1 targeting will test whether genetically defined kidney disease can become a distinct treatment category**

- Data for the APOL1 inhibitor MZE829 will put greater focus on treating APOL1-mediated kidney disease according to its molecular driver rather than phenotype alone. The question will be whether direct APOL1 inhibition can generate sufficient renal benefit to support routine genetic testing and a distinct treatment pathway within heterogeneous conditions such as FSGS





• **Kidney protection will increasingly become a treatment-layering question**

- Kidney-focused datasets involving finerenone, balcinrenone plus dapagliflozin, empagliflozin, semaglutide, tirzepatide and retatrutide will broaden the CKM discussion beyond individual drug classes. The strategic question will be how SGLT2 inhibition, mineralocorticoid receptor modulation and incretin-based therapies will eventually be prioritized or combined as their kidney and cardiovascular benefits increasingly overlap



• **AKI will test the shift from supportive care toward prediction and targeted intervention**

- ASN will feature pharmacologic approaches including isuzinaxib and AZD4144, alongside AI-based models designed to identify patients at risk of acute or persistent kidney injury. The competitive question will be whether earlier risk identification can be linked to effective intervention, allowing AKI to move beyond largely supportive management toward a more active treatment model





Key Sessions To Watch (1/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
22 Oct 2026	Sibeprenlimab: 24-Month VISIONARY Data	Late-Breaking Poster	Jicheng Lv	The 24-month Phase 3 dataset will provide an important test of durability for APRIL inhibition and will help benchmark sibeprenlimab against other emerging IgAN therapies.
22 Oct 2026	Atacicept: ORIGIN 3 IgAN	Late-Breaking Poster	Jonathan Barratt	ORIGIN 3 will provide a major Phase 3 readout for BAFF/APRIL inhibition and will be central to assessing atacicept's position within the emerging IgAN class.
22 Oct 2026	Retatrutide Kidney Parameters in CKD	Late-Breaking Poster	Hiddo J. Heerspink	The analysis will show whether retatrutide's metabolic effects will be accompanied by kidney signals relevant to future CKM treatment positioning.
23 Oct 2026	Sefaxersen: Phase 3 IMaGINATION Interim Analysis	High-Impact Clinical Trial Oral	Jonathan Barratt	The interim Phase 3 analysis will test whether an mRNA-targeted approach can add a differentiated mechanism to an increasingly crowded IgAN landscape.
23 Oct 2026	Isuzinaxib: Phase 2 Contrast-Associated AKI	Late-Breaking Oral	Hyeon-Cheol Gwon	The randomized Phase 2 study will test whether pharmacological intervention can preserve kidney function after contrast exposure in CKD patients.



Key Sessions To Watch (2/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
23 Oct 2026	Zigakibart: 124-Week IgAN Outcomes	Oral	Laura Kooienga	Long-term data will show whether APRIL inhibition can sustain proteinuria remission and immunologic effects through more than two years of treatment.
23 Oct 2026	Iptacopan: APPLAUSE-IgAN Biomarkers	Oral	Dana V. Rizk	The analysis will show whether factor B inhibition will produce sustained alternative-complement suppression and reduced intrarenal inflammatory signaling over 24 months.
23 Oct 2026	Tegoprubart vs Tacrolimus: BESTOW PROs	Oral	Andrew B. Adams	Patient-reported outcomes will test whether tegoprubart can add a treatment-burden and quality-of-life argument to previously reported BESTOW efficacy and safety findings.
24 Oct 2026	FT819 Anti-CD19 CAR-T in Lupus Nephritis	Oral	Shirley W. Pang	Updated Phase 1 data will test whether off-the-shelf CAR-T can generate renal responses with a less-intensive conditioning strategy in refractory lupus nephritis.
24 Oct 2026	MZE829: HORIZON APOL1-Mediated Kidney Disease	Oral	Susan Limb	HORIZON will provide an early test of whether direct APOL1 inhibition can reduce albuminuria sufficiently to support a genetically defined treatment pathway.

Industry-Sponsored Sessions & Focus Areas – ASN Kidney Week 2026





ASN Kidney Week'26 – Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
IgAN targeted treatment and sequencing	Multiple	Povetacicept, atacicept, sibeprenlimab, zigakibart, iptacopan, sparsentan, sefaxersen, telitacicept	Multiple mechanisms will compete for overlapping patients, making sequencing, durability and patient selection increasingly important.
Complement-mediated kidney disease	Multiple	Iptacopan, pegcetacoplan, ravulizumab, crovalimab	Competition will increasingly center on where different complement targets fit across IgAN, C3G, IC-MPGN and other complement-driven diseases.
B-cell, plasma-cell and immune-reset strategies	Multiple	Obinutuzumab, budoprutug, FT819, rituximab, anti-CD38 approaches	Deeper immune intervention will challenge established immunosuppression on durability of response, safety and treatment burden.
FSGS and APOL1-mediated kidney disease	Multiple	MZE829, sparsentan and other FSGS approaches	Direct APOL1 targeting could begin separating genetically defined disease from the broader heterogeneous FSGS treatment pathway.
CKM and metabolic kidney protection	Multiple	Finerenone, balcinrenone + dapagliflozin, empagliflozin, semaglutide, tirzepatide, retatrutide	Increasing overlap in renal and cardiovascular benefit will make treatment layering and patient prioritization more important.





ASN Kidney Week'26 – Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
AKI treatment and risk prediction	Multiple	Isuzinaxib, AZD4144, AI-based prediction models and other investigational approaches	The field will test whether better risk prediction can be coupled with pharmacologic intervention to move AKI beyond supportive care.
Kidney transplantation and immunosuppression	Multiple	Tegoprubart, imlifidase, SmartNTx and other transplant approaches	New immunosuppression and follow-up strategies will test whether established calcineurin-inhibitor-centered management can be improved.
Dialysis modality and remote monitoring	Multiple	High-volume HDF, ELISIO-HX, CloudCath and other dialysis technologies	Competition will extend beyond clearance toward modality choice, remote monitoring, treatment retention and patient experience

Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (1/8)



• **Fresenius Medical Care:**

- Focus Areas: High-Volume Hemodiafiltration, Dialysis Outcomes & U.S. Adoption
- Fresenius will focus on U.S. prescriber and patient experience with high-volume HDF. The session will signal an effort to move the discussion from evidence generation toward practical adoption and integration into routine dialysis care



• **Medtronic:**

- Focus Areas: Resistant Hypertension, Renal Denervation & Nephrology Practice
- Medtronic will focus on the role of renal denervation within nephrology practice. The session will signal an effort to strengthen nephrologist involvement in identifying and referring patients with difficult-to-control hypertension for device-based treatment

Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (2/8)



- **Vantive Healthcare:**

- Focus Areas: KDIGO Guidance & Clinical Implementation
- Vantive will focus on interpretation of proposed KDIGO guidance and its clinical implications. The session will signal an emphasis on translating evolving standards into treatment decisions and kidney-care delivery.

- **Vertex Pharmaceuticals:**

- Focus Areas: IgAN Pathogenesis & Earlier Intervention
- Vertex will focus on moving upstream in IgAN from pathogenic drivers to patient outcomes. The session will signal interest in positioning disease-mechanism intervention earlier in the treatment pathway rather than focusing only on downstream proteinuria control.

Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (3/8)



• **Akebia Therapeutics:**

- Focus Areas: FSGS, Complement & Investigational Mechanisms
- Akebia will focus on investigational mechanisms in FSGS and complement-mediated kidney diseases. The session will signal a broader strategic interest in glomerular disease beyond the company's established anemia presence.



• **Vera Therapeutics:**

- Focus Areas: IgAN & Treatment-Paradigm Evolution
- Vera will focus on how treatment of IgAN will evolve as mechanism-directed therapies become available. The session will support the strategic context around atacicept and the role of BAFF/APRIL targeting within an increasingly crowded treatment pathway.

Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (4/8)



• **Boehringer Ingelheim:**

- Focus Areas: CKM Syndrome, Aldosterone & Residual Kidney Risk
- Boehringer Ingelheim will focus on the role of aldosterone in kidney outcomes within CKM syndrome. The session will signal interest in residual renal risk that persists despite established cardio-kidney therapies and where additional pathway intervention could fit.



• **Ardelyx:**

- Focus Areas: Hyperphosphatemia & Alternative Phosphate Management
- Ardelyx will focus on a different approach to treating hyperphosphatemia. The session will signal continued efforts to shift treatment discussions beyond conventional phosphate-binding strategies in dialysis.



Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (5/8)



- **Novartis:**

- Focus Areas: IgAN Heterogeneity & Treatment Selection
- Novartis will focus on heterogeneity within IgAN and evolving treatment strategies. The session will signal a portfolio approach in which differing disease mechanisms and patient profiles could become increasingly important to treatment selection.



- **Biogen:**

- Focus Areas: IgAN, Membranous Nephropathy & Plasma-Cell Biology
- Biogen will focus on targeting plasmablasts and plasma cells beyond conventional B-cell approaches in IgAN and primary membranous nephropathy. The session will signal interest in deeper intervention against antibody-producing cells as a potential next step in glomerular disease treatment.



Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (6/8)



- **NIPRO:**

- Focus Areas: Expanded Hemodialysis & Membrane Technology
- NIPRO will focus on expanded hemodialysis with ELISIO-HX. The session will signal competition around middle-molecule removal and whether membrane technology can differentiate dialysis beyond conventional high-flux treatment

- **Biogen:**

- Focus Areas: C3G & Primary IC-MPGN
- Biogen will separately focus on treatment of C3 glomerulopathy and primary IC-MPGN. The session will signal continued interest in rare complement-mediated glomerular disease as a targeted therapeutic category

Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (7/8)



- **Alexion / AstraZeneca Rare Disease:**

- Focus Areas: IgAN, Complement Biology & Nephron Loss
- Alexion/AstraZeneca Rare Disease will focus on the link between complement activation, inflammation and nephron loss in IgAN. The session will signal an effort to reinforce complement as a therapeutically actionable component of IgAN pathogenesis.

- **Otsuka:**

- Focus Areas: Sibeprenlimab, IgAN & Patient Selection
- Otsuka will focus specifically on VOYXACT (sibeprenlimab) in adults with primary IgAN at risk of disease progression. The session will signal a practical shift toward identifying appropriate patients and incorporating APRIL inhibition into real-world IgAN management.



Key Industry-Sponsored Sessions at ASN Kidney Week 2026 (8/8)



• Genentech:

- Focus Areas: **Lupus Nephritis & Treatment Selection**
- Genentech will focus on identifying treatment opportunities in **lupus nephritis**. The session will signal an emphasis on **patient selection** and where **more intensive B-cell-directed intervention** could fit within evolving LN treatment pathways.



• AstraZeneca:

- Focus Areas: **Uncontrolled Hypertension & Aldosterone Targeting**
- AstraZeneca will focus on a **novel aldosterone-targeted approach for uncontrolled hypertension**. The session will signal interest in treating **persistent hypertension through disease biology** rather than further intensification of conventional blood-pressure lowering alone.



New Entrants

Asset / Company	2026 Presence
Budoprutug	Preliminary Data from PrisMN, a Phase 2 Study Evaluating the Safety and Efficacy of Budoprutug, an Investigational Low-Fucosylated Anti-CD19 Monoclonal Antibody (mAb), in Patients with Primary Membranous Nephropathy (PMN)
Crovalimab	Crovalimab for Atypical Hemolytic Uremic Syndrome in Pediatric Patients: The Phase 3 COMMUTE-p Trial
Retatrutide	Effects of Retatrutide on Kidney Parameters in Participants with Obesity or Overweight and CKD
ARGX-121	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARGX-121 in Healthy Adult Participants: Results from the Phase 1 First-in-Human Study
WAL0921	Activity of the Novel Anti-Soluble Urokinase Plasminogen Activator Receptor (suPAR) Monoclonal Antibody WAL0921 in People with Diabetic Kidney Disease
ALXN1920	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ALXN1920 in Adults with Primary Membranous Nephropathy
PYC-003	A Phase 1 Study of PYC-003, a Peptide-Oligonucleotide Conjugate That Increases PC1 Expression in Patients with ADPKD
GE8820	GE8820: A Selective IgG4 Degradar for the Treatment of Primary Membranous Nephropathy (PMN)
BHV-1420	Preclinical Characterization of BHV-1420: A Novel TRAP Degradar of Phospholipase A2 Receptor Autoantibodies for Treatment of Membranous Nephropathy



AI / Digital Health Angle at ASN Kidney Week 2026 (1/2)

- **AI and digital-health presentations at ASN Kidney Week 2026 will represent a clinical prediction, decision-support, pathology, and remote-monitoring signal rather than a broad digital-health adoption theme. Sessions will examine AI-based kidney-risk prediction, deep-learning pathology, EHR-integrated clinical decision support, telemedical transplant management, and remote dialysis monitoring**
- **AI activity will be strategically relevant because several presentations will evaluate tools at points where they could influence clinical management. The key signal will be whether externally validated prediction models, clinical decision-support systems, and remote-monitoring technologies can move beyond analytical performance toward actionable risk identification, treatment decisions, and longitudinal kidney care**
- **Key sessions include:**
 - Multicenter AI model identifying preoperative risk profiles for postoperative acute kidney disease (AKD)
 - Artificial Intelligence in Kidney Care: From Pathology to Prediction: Oral session covering deep-learning kidney pathology, computational image analysis, ADPKD imaging, risk prediction, and AI-supported kidney-care applications



AI / Digital Health Angle at ASN Kidney Week 2026 (2/2)

- Treat CKD, an EHR-integrated clinical decision-support tool for risk-based CKD care in primary care
- SmartNTx trial comparing telemedical management with standard aftercare following kidney transplantation
- CloudCath remote monitoring and peritonitis-related outcomes in peritoneal dialysis
- CloudCath remote monitoring and retention on peritoneal dialysis
- Wearable real-time creatinine monitoring for early detection of changing kidney function
- ALMA-CKD trial of clinical decision-support triggers to improve CKD screening and detection
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - Risk prediction through machine-learning models for AKD and other kidney outcomes
 - Clinical decision support through EHR-integrated tools for CKD detection and management
 - Kidney pathology and imaging through deep-learning and computational image analysis
 - Remote patient monitoring through telemedicine, peritoneal dialysis monitoring, and wearable kidney-function technologies



What We're Watching for Post-ASN Kidney Week 2026

- Whether povetacicept, atacicept, sibeprenlimab, zigakibart, iptacopan and sefaxersen generate sufficiently differentiated data to provide clearer treatment-selection and sequencing logic in IgAN rather than further increasing therapeutic complexity
- Whether MZE829 demonstrates sufficient renal activity and safety in the HORIZON study to strengthen the case for direct APOL1 inhibition and a genetically defined treatment pathway in APOL1-mediated kidney disease
- Whether FT819 and budoprutug generate sufficient renal and immune-response signals to strengthen the case for deeper CD19-directed intervention in lupus nephritis and primary membranous nephropathy
- Whether the randomized Phase 2 isuzinaxib results provide enough evidence of kidney-function preservation to support further development of pharmacologic intervention for contrast-associated AKI, while the SERENIA presentation clarifies the development strategy for NLRP3 inhibition with AZD4144 in sepsis-associated AKI
- Whether BESTOW patient-reported outcomes provide additional differentiation for tegoprubart versus tacrolimus on treatment burden and health-related quality of life in kidney transplant recipients

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM